Please login to the form below

Not currently logged in
Email:
Password:

European bioinformatics institute appoints GSK's Dr Andrew Leach

He joins the EMBL-EBI as head of chemistry services

EMBL EBI Dr Andrew LeachThe European Bioinformatics Institute (EBI) has appointed Dr Andrew Leach as head of chemistry services, who will take up the position on 1 September.

Dr Leach moves to the institute - a part of the European Molecular Biology Laboratory (EMBL) - from GSK Research and Development, which he joined in 1994 as a research scientist and manager.

From there, Dr Leach progressed to director of computational chemistry, Europe before taking on his most recent role as head of biomolecular sciences in which he delivered biophysics, structural biology and bioanalytical data analysis and expertise.

Between 2006 and 2015, he served as a trustee of the Cambridge Crystallographic Data Centre and was editor of the Journal of Computer-Aided Molecular Design from 1997 to 2012.

Dr Rolf Apweiler, director of EMBL-EBI, said: “Dr Leach is greatly respected in the pharma world and brings with him a wealth of knowledge and experience in drug discovery and cheminformatics.

“As a user of EMBL-EBI resources throughout his career, Andrew brings unique insights into the pharma industry's user requirements and an exciting vision for future exploitation of opportunities in data, analytics and computation.”

Dr Leach said: “I am honoured to have been chosen to take on the leadership of EMBL-EBI's highly successful chemistry services.

“I know first-hand the huge value that EMBL-EBI's resources bring to bench scientists in the industry and am looking forward to taking EMBL-EBI's chemical biology data services to the next level.”

29th March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics